This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Myasthenia gravisMyasthenia Gravis (MG)

Contents and key points
ItemDetails
A. Classification codesICD-10: G70.0 | Special Copayment Reduction: V012 | Coverage period: 5 years
B. SynonymsMyasthenia gravis (MG), ocular myasthenia gravis, generalized myasthenia gravis, thymoma-associated myasthenia gravis
C. Adult onsetLikelihood of first onset in adulthood: high — Peak onset in women in their 20s–30s and in men in their 60s–70s; thymoma-associated MG most common in the 40s–60s
1. History1672: described by Willis; 1895: named by Jolly; 1960s: AChR autoantibodies discovered; 1970s–80s: treatment system established; later: MuSK and LRP4 antibodies discovered
2. CausesImpaired neuromuscular junction transmission due to autoantibodies such as AChR antibodies (80%), MuSK antibodies (5–8%), and LRP4 antibodies (2–3%); associated with thymoma (10–15%) and thymic hyperplasia (65%)
3. GeneticsNon-hereditary autoimmune; HLA associations (HLA-B8/DR3: early-onset women; HLA-B7/DR2: late-onset men); familial cases rarely reported
4. General epidemiologyPrevalence about 15–20 per 100,000; incidence about 0.3–2.8 per 100,000 per year; bimodal age peaks (women 20s–30s, men 60s–70s); late onset recently increasing
5. PathophysiologyAChR-Ab: receptor cross-linking promotes degradation, complement activation, internalization; MuSK-Ab: impaired AChR clustering; induction of autoreactivity by thymic T cells
6. SymptomsWeakness that worsens with fatigue; ptosis and diplopia (ocular form), dysphagia, dysarthria, limb weakness; myasthenic crisis (respiratory failure)
7. SignsFatigable ptosis, limited eye movement, positive Kugelberg fatigue test, ice pack test, CMAP decrement from the 4th response on repetitive nerve stimulation
8. ScreeningClinical suspicion from fatigable weakness + ptosis/diplopia pattern; AChR and MuSK antibody testing; repetitive nerve stimulation; thymic CT
9. DiagnosisSerum antibodies (AChR, MuSK, LRP4), repetitive nerve stimulation (decrement of 10% or more), single-fiber EMG (increased jitter), edrophonium test, thymic CT/MRI
10. TreatmentPyridostigmine (symptom relief), steroids and immunosuppressants, IVIG and plasma exchange (crisis, preoperative), thymectomy (AChR+, under age 65); new drugs eculizumab and efgartigimod
11. PrognosisMortality 1–3% with modern treatment; complete stable remission about 20%; most have good quality of life with treatment; myasthenic crisis is the main cause of death
12. PreventionNo specific prevention; avoid drugs that cause exacerbation; manage infection, stress, and overwork; thymectomy improves long-term remission rates
References10 key references (including PMID/DOI)

1. History

The clinical description of myasthenia gravis (MG) began in 1672, when the English physician Thomas Willis recorded a case of paralysis of the limb and speech muscles worsened by fatigue. In 1877, Samuel Wilks systematically reported cases of bulbar palsy and generalized weakness, and in 1895 the German neurologist Friedrich Jolly observed the characteristic muscle fatigue caused by repetitive muscle stimulation at the level of the neuromuscular junction and proposed the name 'Myasthenia gravis pseudoparalytica'.

In 1934, the Scottish physician Mary Walker reported that physostigmine (an AChE inhibitor) dramatically improves MG symptoms, pointing the pathophysiology toward impaired neuromuscular junction transmission. In the 1960s, Patrick and Lindstrom succeeded in reproducing an MG-like disease (EAMG) in experimental animals with AChR from the electric eel, and autoantibodies to AChR were confirmed to be detectable in human MG. This was a landmark discovery that established the autoimmune mechanism of MG. In the 1970s–80s, the clinical efficacy of major treatments such as pyridostigmine, steroids, thymectomy, plasma exchange, and IVIG was systematically demonstrated. In 2001, MuSK (muscle-specific kinase) antibodies were reported to be detected in about 40% of AChR antibody-negative MG patients, and various autoantibodies such as LRP4, agrin, titin, and RyR were later discovered. In 2017, with FDA approval of eculizumab (a complement C5 inhibitor) for the treatment of AChR-positive generalized MG, the era of complement inhibition therapy began, and efgartigimod (an FcRn blocker) was additionally approved in 2021–2022.

2. Causes

MG is an autoimmune disease that causes impaired neurotransmission at the neuromuscular junction (NMJ). Clinical features, association with thymic abnormalities, and treatment response differ according to the type of the main autoantibody.

3. Genetics

MG is generally not a hereditary disease and is not explained by a single-gene mutation. Familial occurrence is rare, at about 3–5%. However, genetic predisposition may influence the development of autoimmune responses.

Associations with HLA genes have been relatively well studied. Early-onset (under age 50) AChR-positive MG in women is strongly associated with HLA-B8, DR3, and DQ2. Late-onset (age 50 or older) AChR-positive MG in men is associated with HLA-B7 and DR2. MuSK antibody-positive MG is associated with HLA-DR14 and DQ5, which is clearer mainly in those of Southern European and African descent. Polymorphisms of immune regulatory genes such as PTPN22 and CTLA4 have also been reported to be associated with MG risk. Congenital myasthenic syndromes (CMS) are genetically completely different diseases and should not be confused with MG. Routine genetic testing of the families of MG patients is not recommended in clinical practice.

4. General epidemiology

The prevalence of MG is about 15–20 per 100,000 population, relatively high among rare diseases. The incidence is about 0.3–2.8 per 100,000 population per year, varying between studies. It occurs worldwide, and prevalence continues to increase owing to improvements in diagnostic technology and awareness.

Age of onset shows a bimodal peak. The first peak is in women in their 20s–30s (early-onset group), and the second peak is in men in their 60s–70s. The sex ratio shifts from female predominance under age 50 to male predominance at age 50 or older. Recently, with the growth of the elderly population, the proportion of late-onset MG has risen to account for about 30–40% of the total. An epidemiological feature in Asia is that ocular MG accounts for a relatively higher proportion than in Western countries. Thymoma-associated MG commonly occurs at about age 40–60.

5. Pathophysiology

The pathogenic mechanism of MG is autoantibody-mediated impairment of transmission at the neuromuscular junction (NMJ). The mechanism differs according to the type of autoantibody.

Mechanism of AChR antibodies: Three mechanisms act in combination. First, activation of the classical complement pathway: IgG1/IgG3 antibodies bind to AChR and activate complement, and the membrane attack complex (MAC) forms on the postsynaptic membrane, directly destroying AChR and the muscle fiber membrane. Second, receptor cross-linking (antigenic modulation): bivalent antibodies cross-link adjacent AChRs, promoting receptor internalization (endocytosis) and degradation and reducing postsynaptic AChR density. Third, functional blockade: some antibodies directly block the ACh binding site or the ion channel. The three mechanisms act together to lower the safety factor of neuromuscular transmission.

Mechanism of MuSK antibodies: As IgG4 antibodies, they do not activate complement. MuSK is a key protein that receives signals from agrin and induces AChR clustering. Anti-MuSK antibodies interfere with the agrin-MuSK interaction and inhibit MuSK autophosphorylation, causing impaired AChR clustering and dispersal of existing clusters. This leads to collapse of the postsynaptic structure.

Role of the thymus: The thymus (especially in thymic hyperplasia) contains myoid cells that cross-react with AChR, and in an abnormal thymic microenvironment autoreactive T cells mature and help B cells produce autoantibodies in the periphery.

6. Symptoms

The core clinical feature of MG is fatigable (fluctuating) weakness that worsens with exertion and improves after rest. All voluntary muscles can be involved, but the extraocular, bulbar, neck, limb, and respiratory muscles are especially commonly involved.

Ocular symptoms (initial symptom in about 50%): Ptosis is the most common initial symptom. One or both eyelids droop, worsening later in the day (afternoon, evening). Diplopia results from extraocular muscle imbalance and varies with the direction of gaze. Ocular MG is likely to remain confined to the ocular muscles if it does not progress to the generalized form within 2 years.

Bulbar and neck symptoms: Dysphagia, dysarthria (nasal speech, speech fatigue), difficulty chewing. "Head drop" due to weakness of the neck extensors. Bulbar and neck involvement is prominent in MuSK antibody-positive MG.

Limb weakness: Proximal predominance (difficulty raising the arms, difficulty climbing stairs). Fatigue increases during exercise and recovers temporarily after rest.

Myasthenic crisis: A life-threatening state in which respiratory failure develops due to involvement of the respiratory muscles. Infection, surgery, certain drugs, and emotional stress are triggering factors. Immediate ICU admission and mechanical ventilation are needed.

7. Signs

Physical examination findings that support a diagnosis of MG are as follows.

Fatigable ptosis: Ptosis appears or worsens after sustained upgaze (60–90 seconds) (Kugelberg fatigue test). Cogan lid twitch, in which ptosis appears on the opposite side when one eyelid is lifted, may be observed.

Ice pack test: Improvement of ptosis after applying an ice pack to the eyelid for 2 minutes strongly supports MG (sensitivity ~77%, specificity ~98%). This is because cooling temporarily inhibits AChE activity.

Speech fatigue: Nasal speech gradually worsens or the voice changes during sustained speaking or reading sentences aloud.

Respiratory function: Reduced FVC, MIP, MEP; essential for assessing myasthenic crisis. The need for mechanical ventilation is judged by the "20-30-40 rule" (FVC <20 mL/kg, MIP >-30, MEP <40).

Edrophonium test (Tensilon test): Positive if ptosis or extraocular muscle paralysis improves temporarily after intravenous injection of edrophonium, a short-acting AChE inhibitor. It is now less used because of the risk of cardiac arrhythmia.

Normal sensory system, preserved reflexes: In MG, tendon reflexes and sensation are preserved as normal, an important point of differentiation from other neuromuscular diseases.

8. Screening

Clinical suspicion of MG is based on a pattern of fatigable weakness (worsening with activity, improving with rest). In particular, MG should be considered first when ptosis and diplopia are present and fluctuate during the day.

Serum antibody testing: Anti-AChR antibodies (radioimmunoprecipitation assay, RIPA): sensitivity about 80% in generalized MG and about 50% in the ocular form. Anti-MuSK antibodies: performed in AChR-negative patients. Anti-LRP4 antibodies: additionally performed in double-negative patients. Even if antibody-negative, proceed to the next tests if clinically suspected.

Electrophysiological testing: Repetitive nerve stimulation (RNS): positive if the CMAP amplitude of the 4th–5th response decreases by 10% or more (decremental response) with 3 Hz repetitive stimulation. Single-fiber electromyography (SFEMG): the most sensitive electrophysiological test (sensitivity ~95%). Increased jitter is characteristic.

Thymic imaging: Thymoma and thymic hyperplasia are evaluated by chest CT (contrast-enhanced CT preferred) or MRI. Thymic imaging is needed in all patients at the time of MG diagnosis.

9. Diagnosis

Diagnosis of MG is made by combining the characteristic clinical picture, serum antibodies, electrophysiological testing, and imaging. The classification criteria and clinical assessment scales of the MGFA (Myasthenia Gravis Foundation of America) are used.

Serum antibodies: Anti-AChR antibodies (measured by RIPA), anti-MuSK antibodies (ELISA/FACS), anti-LRP4 antibodies (CBA). Antibody titers are not fully proportional to disease severity but can be used as a reference for monitoring treatment response. In thymoma-associated MG, anti-titin and anti-RyR antibodies are often positive.

Repetitive nerve stimulation (RNS): Performed both distally (wrist–abductor digiti minimi) and proximally (deltoid, facial nerve–orbicularis oculi). A decrement of 10% or more is the criterion for a positive result. Sensitivity is higher in MuSK MG. Single-fiber electromyography (SFEMG): the most sensitive but technically difficult and requires specialized facilities.

MGFA severity classification: Classified as I (ocular), II (mild generalized), III (moderate generalized), IV (severe generalized), and V (intubation required), and used to determine treatment intensity.

Clinical scales such as MG-ADL and QMG: Standardized scales are used to assess treatment response. The MG-ADL (8 items) and the quantitative MG score (QMG, 13 items) are representative.

10. Treatment

MG treatment consists of three pillars: symptom relief, immunomodulation, and surgical treatment when needed. Treatment is individualized according to antibody subtype and MGFA class.

Acetylcholinesterase (AChE) inhibitors: Pyridostigmine is the first-line symptomatic treatment. It inhibits AChE, raising ACh concentration in the synaptic cleft and enhancing neuromuscular transmission. Dose: 30–120 mg given every 3–6 hours. In MuSK antibody-positive MG, caution is needed because it may be insufficiently effective or worsen cholinergic symptoms (muscle cramps, hypersecretion).

Immunosuppressive therapy: Steroids (prednisolone): the most widely used. To prevent abrupt worsening at initiation (steroid dip), start at a low dose and increase slowly. Management of adverse effects of long-term use is needed. Steroid-sparing immunosuppressants: azathioprine, mycophenolate mofetil, and cyclosporine are used. Because their onset of effect is slow, they are combined with steroids, which are then tapered.

Acute-phase treatment (crisis, preoperative preparation): IVIG (2 g/kg, 5 days) or plasma exchange (5–7 sessions) is used. Both have the advantage of rapid onset but are temporary.

Thymectomy: The MGTX randomized controlled trial (2016) demonstrated that thymectomy increases long-term remission rates in AChR antibody-positive patients under age 65 with generalized MG. Thymectomy is indicated in all MG patients with thymoma. The benefit of thymectomy in MuSK antibody-positive MG has not been established.

New targeted therapies: Eculizumab (Soliris): complement C5 inhibitor; FDA-approved for AChR-positive generalized MG (2017). Ravulizumab: long-acting C5 inhibitor; FDA-approved in 2022. Efgartigimod (Vyvgart): FcRn blocker; FDA-approved in 2021. Rituximab: effective in MuSK antibody-positive MG (off-label). Inebilizumab: anti-CD19 monoclonal antibody; under phase 3 study in AChR/MuSK MG.

11. Prognosis

With advances in modern treatment, the prognosis of MG has greatly improved. Mortality, which once reached 20–30%, has now fallen to about 1–3%, and the main causes of death are myasthenic crisis and thymoma-related complications.

Clinical outcomes: Complete stable remission (CSR: no symptoms and no medication for at least 1 year) is achieved in about 20%. Minimal manifestation status can be achieved in about 50–60%. If the disease starts as the ocular form and does not convert to the generalized form within 2 years, the subsequent risk of generalized involvement becomes markedly lower.

After thymectomy: Thymectomy significantly increases long-term (3–5 year) remission rates (MGTX study). In MG with thymoma, clinical improvement after tumor removal is observed in some.

Prognosis by subtype: MuSK antibody-positive MG tends to be more severe and harder to treat than AChR-positive MG, but sometimes responds well to rituximab. The prognosis of ocular MG is better than that of the generalized form, but reduced quality of life due to diplopia and ptosis may persist.

12. Prevention

There is no specific method to prevent the development of MG itself. However, strategies to prevent exacerbations and myasthenic crisis in patients already diagnosed with MG are important.

Avoiding drugs that exacerbate MG: Drugs that can worsen MG include aminoglycoside antibiotics, fluoroquinolones, macrolides, magnesium, chloroquine, D-penicillamine, beta-blockers, calcium channel blockers, imipenem, telithromycin, and others. A history of MG should be checked before prescribing these drugs.

Infection prevention and management: Infection is the most common trigger of myasthenic crisis. Influenza and pneumococcal vaccination is recommended (live vaccines are contraindicated while taking immunosuppressants). When infection occurs, early antibiotic treatment and adjustment of immunosuppressants are needed.

Managing stress and overwork: Emotional stress, sleep deprivation, and excessive physical activity can worsen MG symptoms, so maintaining a regular lifestyle is recommended.

Thymectomy: In AChR-positive MG, appropriate thymectomy has a preventive effect of increasing long-term remission rates and reducing immunosuppressant doses.

References

  1. Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. DOI: 10.1038/s41572-019-0079-y
  2. Gilhus NE, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. Eur J Neurol. 2024;31(4):e16229. DOI: 10.1111/ene.16229
  3. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511-522. PMID: 27509100
  4. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN). Lancet Neurol. 2017;16(12):976-986. PMID: 29066163
  5. Muppidi S, Barnett C, Bhatt M, et al. Efficacy and safety of efgartigimod in adults with generalized myasthenia gravis (ADAPT). JAMA Neurol. 2023;80(2):116-123. PMID: 36622703
  6. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419-425. PMID: 27358333
  7. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475-490. PMID: 19375665
  8. Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018;36(2):253-260. PMID: 29655448
  9. Kerty E, Elsais A, Argov Z, et al. EFNS/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687-693. PMID: 24471489
  10. Guideline for the management of myasthenic syndromes. Clin Med (Lond). 2023;23(6):527-548. PMID: 38123875